News
Public · Published
Barclays maintains Teladoc Health at Equal-Weight, raises price target to $9 from $7
Barclays kept its Equal-Weight rating on Teladoc Health and raised its price target to $9 from $7. The new target is 1.2% above the stock's Nov. 3 closing price of $8.89; five recent analyst targets cited in the article range from $6.50 to $10.
Published:
Updated:
What happened
Barclays kept its Equal-Weight rating on Teladoc Health and raised its price target to $9 from $7. The new target is 1.2% above the stock’s Nov. 3 closing price of $8.89; five recent analyst targets cited in the article range from $6.50 to $10.
Confirmed
Global impact / market context
The higher target signals Barclays sees slightly more room for the shares to rise, but its unchanged Equal-Weight rating does not indicate a stronger recommendation. The target’s small stated upside may limit how much this particular note changes investor expectations or positioning.
Analyst inference
Other recent analyst views in the article span ratings from Hold to Outperform and targets from $6.50 to $10. That spread shows disagreement about Teladoc’s value, so Barclays’ $9 target sits within the reported range rather than standing out as an extreme view.
Confirmed
What to watch
- Compare later analyst updates with Barclays’ $9 target and the reported $6.50–$10 range to see whether opinions converge or remain widely divided. Analyst inference
- Watch for changes to Barclays’ Equal-Weight rating; the article reports a target increase but no rating change, so a new rating would signal a distinct shift. Analyst inference
- Track Teladoc’s share price against the $9 target, which the article says is 1.2% above the Nov. 3 close of $8.89. Confirmed
Evidence
- Original source link unavailable